Tamoxifen enhances the anti-proliferative effect of roscovitine, a selective cyclin-dependent kinase inhibitor, on human ER-positive human breast cancer cells

Journal of Experimental Therapeutics and Oncology

Volumn 9, Issue 1, 2011, Pages 37-45

  Gritsch, David ^a   Maurer, Margarita ^a   Zulehner, Nora ^a   Wȩsierska Ga̧dek, Józefa ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anti estrogens; Apoptosis, cell cycle arrest; Cyclin dependent kinases; Estrogen; Inhibitors of cyclin dependent kinases; Roscovitine

Indexed keywords

ESTROGEN RECEPTOR; ROSCOVITINE; TAMOXIFEN;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL POPULATION; CELL PROLIFERATION; CELL STRAIN MCF 7; COCULTURE; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLIN-DEPENDENT KINASES; DRUG SYNERGISM; ESTROGEN RECEPTOR ALPHA; FLOW CYTOMETRY; G1 PHASE; HUMANS; IMMUNOBLOTTING; MULTIPLE MYELOMA; PURINES; S PHASE; TAMOXIFEN; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79251510568     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. American Cancer Society (2005/2006). "Breast Cancer Facts & Figures.
2. Fujita, M., T. Urano, et al. (2002). "Estrogen activates cyclin-dependent kinases 4 and 6 through induction of cyclin D in rat primary osteoblasts." Biochem Biophys Res Commun 299(2): 222-228. (Pubitemid 35373701)
3. Havlicek, L., J. Hanus, et al. (1997). "Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds." J Med Chem 40(4): 408-412. (Pubitemid 27080019)
4. Janicke, R. U., M. L. Sprengart, et al. (1998). "Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis." J Biol Chem 273(16): 9357-9360. (Pubitemid 28183012)
5. Key, T. J., P. K. Verkasalo, et al. (2001). "Epidemiology of breast cancer." Lancet Oncol 2(3): 133-140.
6. Matthews, J. and J. A. Gustafsson (2003). "Estrogen signaling: a subtle balance between ER alpha and ER beta." Mol Interv 3(5): 281-292.
7. Maurer, M., O. Komina, et al. (2009). "Roscovitine differentially affects asynchronously growing and synchronized human MCF-7 breast cancer cells." Ann N Y Acad Sci 1171: 250-256.
8. Nathanson, K. L., R. Wooster, et al. (2001). "Breast cancer genetics: what we know and what we need." Nat Med 7(5): 552-556. (Pubitemid 32448321)
9. Nilsson, S., S. Makela, et al. (2001). "Mechanisms of estrogen action." Physiol Rev 81(4): 1535-1565.
10. Perou, C. M., T. Sorlie, et al. (2000). "Molecular portraits of human breast tumours." Nature 406(6797): 747-752.
11. Prall, O. W., E. M. Rogan, et al. (1998). "c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry." Mol Cell Biol 18(8): 4499-4508.
12. Rachez, C. and L. P. Freedman (2001). "Mediator complexes and transcription." Curr Opin Cell Biol 13(3): 274-280.
13. Riggs, B. L. and L. C. Hartmann (2003). "Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice." N Engl J Med 348(7): 618-629.
14. Ring, A. E., I. E. Smith, et al. (2004). "Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer." Br J Cancer 91(12): 2012-2017.
15. Rogalinska, M., J. Z. Blonski, et al. (2010). "R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis." J Cell Biochem 109(1): 217-235.
16. Russo, I. H. and J. Russo (1998). "Role of hormones in mammary cancer initiation and progression." J Mammary Gland Biol Neoplasia 3(1): 49-61.
17. Smith, C. L. (1998). "Cross-talk between peptide growth factor and estrogen receptor signaling pathways." Biol Reprod 58(3): 627-632. (Pubitemid 28117059)
18. Vindelov, L. L., I. J. Christensen, et al. (1983). "A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis." Cytometry 3(5): 323-327.
19. Wesierska-Gadek, J., E. Bohrn, et al. (2000). "Differential susceptibility of normal and PARP knock-out mouse fibroblasts to proteasome inhibitors." J Cell Biochem 78(4): 681-696.
20. Wesierska-Gadek, J., A. Borza, et al. (2009). "Impact of roscovitine, a selective CDK inhibitor, on cancer cells: bifunctionality increases its therapeutic potential." Acta Biochim Pol 56(3): 495-501.
21. Wesierska-Gadek, J., Borza, A., Walzi, E., Krystof, V., Maurer M., Komina, O. & Wandl, S. (2009) Outcome of treatment of human HeLa Cervical cancer cells with roscovitine depends on the dosage and cell cycle status prior to the treatment. J Cell Biochem 106(5): 937-955.
22. Wesierska-Gadek, J., M. Gueorguieva, et al. (2005). "Roscovitine- induced up-regulation of p53AIP1 protein precedes the onset of apoptosis in human MCF-7 breast cancer cells." Mol Cancer Ther 4(1): 113-124.
23. Wesierska-Gadek, J., M. Gueorguieva, et al. (2005). "A new multiplex assay allowing simultaneous detection of the inhibition of cell proliferation and induction of cell death." J Cell Biochem 96(1): 1-7.
24. Wesierska-Gadek, J., S. B. Hajek, et al. (2008). "Pleiotropic effects of selective CDK inhibitors on human normal and cancer cells." Biochem Pharmacol 76(11): 1503-1514.
25. Wesierska-Gadek, J., D. Schloffer, et al. (2004). "Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout cells to antitumor triazoloacridone C-1305 is associated with permanent G2 cell cycle arrest." Cancer Res 64(13): 4487-4497.
26. Wesierska-Gadek, J., D. Schloffer, et al. (2002). "Escape of p53 protein from E6-mediated degradation in HeLa cells after cisplatin therapy." Int J Cancer 101(2): 128-136.
27. Wesierska-Gadek, J. and G. Schmid (2000). "Overexpressed poly(ADP-ribose) polymerase delays the release of rat cells from p53-mediated G(1) checkpoint." J Cell Biochem 80(1): 85-103.
28. Wesierska-Gadek, J., T. Schreiner, et al. (2006). "Phenol red reduces ROSC mediated cell cycle arrest and apoptosis in human MCF-7 cells." J Cell Biochem 98(6): 1367-1379. (Pubitemid 44141844)
29. Wesierska-Gadek, J., T. Schreiner, et al. (2007). "Phenol red in the culture medium strongly affects the susceptibility of human MCF-7 cells to roscovitine." Cell Mol Biol Lett 12(2): 280-293.
30. Wojciechowski, J., M. Horky, et al. (2003). "Rapid onset of nucleolar disintegration preceding cell cycle arrest in roscovitine-induced apoptosis of human MCF-7 breast cancer cells." Int J Cancer 106(4): 486-495.